TETRATHERIX LIMITED (TTX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TTX

TTX - TETRATHERIX LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -0.37
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$5.25

11 Jun
2026

-0.270

OPEN

$5.53

-4.89%

HIGH

$5.53

38,678

LOW

$5.20

TARGET
$7.15 36.2% upside
FNARENA'S MARKET CONSENSUS FORECASTS
TTX: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 18.7 - 21.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202320242025
EPS Basic xxxxxx-18.7
DPS All xxxxxx0.0
Sales/Revenue xxxxxx0.0 M
Book Value Per Share xxxxxx54.1
Net Operating Cash Flow xxxxxx-2.7 M
Net Profit Margin xxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202320242025
Return on Capital Employed xxxxxx-92.09 %
Return on Invested Capital xxxxxx-77.08 %
Return on Assets xxxxxx-56.71 %
Return on Equity xxxxxx-92.09 %
Return on Total Capital xxxxxx-37.11 %
Free Cash Flow ex dividends xxxxxx-3.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202320242025
Short-Term Debt xxxxxx0 M
Long Term Debt xxxxxx2 M
Total Debt xxxxxx2 M
Goodwill - Gross xxxxxx-
Cash & Equivalents - Generic xxxxxx29 M
Price To Book Value xxxxxx6.06

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202320242025
Capex xxxxxx0.6 M
Capex % of Sales xxxxxx-
Cost of Goods Sold xxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxx6 M
Research & Development xxxxxx1 M
Investments - Total xxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

11/06/2026

1

Speculative Buy

$7.15

36.19%

Tetratherix has completed a placement of $15m at $6 a share to fund expansion of its production facility and Morgans updates its modelling to reflect the new capital.

The broker also takes a more optimistic stance regarding US FDA approval for dental/orthopaedic products, increasing the probability of success to 85%.

The company has reported positive results from independent studies supporting its Tetramatrix drug delivery platform which showed the polymer can safely carry and protect fragile drugs when delivered through the nose.

New patents have also been announced to strengthen intellectual property, covering specific drug/polymer combinations. Morgans retains a Speculative Buy rating, continuing to be impressed with the scalability of the platform. Target is raised to $7.15 from $6.84.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -21.00 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -21.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

TTX STOCK CHART

FNArena News on TTX

1
Next Week At A Glance – 1-5 June 52026

May 29 2026 - Weekly Reports
2
FNArena Corporate Results Monitor – 25-02-2026

Feb 25 2026 - Australia
3
FNArena Corporate Results Monitor – 01-09-2025

Sep 01 2025 - Australia